Catalyst Science Discovery Centre appoints director
Widnes, Cheshire-based firm welcomes Stephen Youd-Thomas
Stephen Youd-Thomas runs a successful corporate and social responsibility consultancy and was formerly head of social goals at the Co-operative Group.
‘This is a wonderful opportunity to help develop the work of the UK's only science discovery centre with chemistry as its main theme. Catalyst brings chemistry alive for thousands of young people from across the North West and beyond and hopefully this experience will encourage many of them to consider a career in science in the future,’ he said.
Catalyst is an independent charitable trust operated by Catalyst Science Discovery Centre and Museum Trust.
You may also like
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
![Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker]()
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker
New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Logistics
![Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa]()
Imara Sickle Cell Framework launches to coordinate diagnosis-to-treatment care across Africa
Initial implementation begins in Uganda, Kenya and Côte d'Ivoire, connecting screening, diagnosis, referral and long-term management into a unified pathway as the continent accounts for nearly 80% of the global disease burden
Research & Development
![BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset]()
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset
The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
Regulatory
![NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development]()
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency